We are committed to launching products that make a difference in people’s lives. We work across a product’s lifecycle, supporting biotech, pharmaceutical, and medical technology companies across the globe.
Our team provide unequalled accuracy and quality whilst delivering all aspects of systematic reviews, meta-analyses and patient-level data analyses.
We develop a range of robust health economic models that meet the commercial needs of our clients from simple Markov models to complex discrete event simulations.
Health Technology Assessment
We have extensive experience delivering successful HTA submissions in the UK and across the globe.
We effectively communicate the value of your products in a logical and insightful manner; from internal value dossiers to external scientific publications.
Pricing & Reimbursement
We partner with our clients to develop strategies for global pricing and reimbursement, harnessing our extensive KOL and payer network.
“FIECON exceeds my expectations by genuinely trying to achieve the best outcomes for our company. Their flexibility to adapt to unexpected changes and apply technical rigour, while respecting the commercial focus of the company is unparalleled. We see FIECON as part of our extended team.”Senior Market Access Manager, Mid-sized Pharma
“FIECON’s highly skilled expert team helped us to successfully tackle a number of tough pricing and access challenges. Apart from their flawless technical expertise, we have a reliable thought partner to pressure test new ideas and strategies that have a broader relevance than purely health economic aspects.”Disease Area Director, Big Pharma
“It was brilliantly smart and very well explained. It seems obvious now but that is what genius is, making complex things appear simple.”Associate Director, Mid-sized Pharma
“FIECON are my go to trusted partner. The team deliver high-quality work to timeline, every time. But more than this, FIECON has worked as part of our team, working towards achieving the best possible outcome by providing high level strategic input and challenge during our discussions.”Market Access Director, Small Biotech
“FIECON’s strategic approach to problem solving is a breath of fresh air. We highly value their HTA knowledge and expertise, and they consistently deliver the best solution for us.”Value Demonstration & Access Lead, Big Pharma
“It is a pleasure to work with FIECON. The team are passionate about what they do and it really shows in their high-quality, creative solutions. Working with FIECON gives your projects the highest chance of success.”Senior Vice President, Small Biotech
NICE METHOD REVIEW
Mark Fisher, our Managing Director, participated and gave evidence in the Access to Medicines and Medical Devices All-Party Parliamentary Group (APPG) NICE Methods Review inquiry at the House of Commons in May. The APPG report has now been published which provides clear recommendations and suggestions for crucial areas for future research and work outside of the NICE review.
Contact Mark for more information about how this may impact your products, and how FIECON can help you navigate the best path for you going forward.
ON SITE AT ISPOR
FIECON will be at ISPOR in Copenhagen in November and on-hand to discuss the latest thinking on how to bring products to market and what we can do to help our clients. Please contact our Commercial Director, firstname.lastname@example.org if you would like to arrange a CEModelBuilder demo, to hear about our new product or to talk about how FIECON can support you.
HOSTED AT HOUSE OF COMMONS
Mark Fisher, our Managing Director, was speaking at the House of Commons alongside Sir Andrew Dillon (NICE), Helen Knight (NICE), and Karl Claxton (University of York) as part of the APPG inquiry into the NICE STA and HST methods. For full notes please email email@example.com - key topics of discussion surrounded how NICE processes can look to close the gap between appraisals for rare and ultra-rare medicines, the role of NICE and NHS England in the assessment of budget impact, whether wider societal costs should be considered for the future, and much more.
MODELS IN MINUTES
Building cost-effectiveness models which can successfully demonstrate product value, can be time consuming and at the mercy of the developer.
Poorly designed models and human error can adversely affect commercial strategy.
Can you afford to make these mistakes?
FIECON can help you build best-in-class cost-effectiveness models whilst significantly reducing building time. We have built a platform which automates the design and building-process of Excel-based cost-effectiveness models.
FIECON Model Builder can help you reduce the risk of human error and build high quality models in a matter of minutes rather than weeks. Our intuitive online interface leads to the quick and easy generation of customised models.
Give yourself the best chance of success; save time and money with the right cost-effectiveness model from FIECON Model Builder. Get in touch with our Commercial Director, firstname.lastname@example.org, to book a demo or find out more.